[Hematopoietic stem cell transplantation in the era of new molecular-targeted therapies].
Recent advances in the field of molecular-targeted therapy have revolutionized the treatment of hematological malignancies. Consequentially, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) has dramatically changed. However, allo-HSCT remains vital in the treatment of hematological malignancies because cure is rarely achieved by targeted therapy only. In the new era of molecular-targeted treatment, its incorporation into allo-HSCT is key to achieving therapeutic success. In particular, the understanding of the immune impact of molecular-targeted therapy on graft-versus-host-disease and graft-versus-leukemia is essential to improve the outcome of allo-HSCT.